Interferon-λ4 ( IFNL4) transcript expression in human liver tissue samples

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Amanzada, Ahmad ^a   Kopp, Waltraut ^a   Spengler, Ulrich ^b   Ramadori, Giuliano ^a   Mihm, Sabine ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; MESSENGER RNA; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IFNL4 GENE; IL28 GENE; IL29 GENE; IN VIVO STUDY; LIVER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; VIRUS LOAD; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ADULT; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; RNA, MESSENGER; VIRAL LOAD;

EID: 84893430467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084026     Document Type: Article

References (30)

1. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135: 44-53. doi: 10.1016/j.pharmthera.2012.03.006
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68. doi: 10.1038/ni873 (Pubitemid 36104710)
3. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77. doi: 10.1038/ni875 (Pubitemid 36109115)
4. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906. doi: 10.1002/hep.21312 (Pubitemid 46489554)
5. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, et al. (2010) Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52: 822-832. doi: 10.1002/hep.23743
6. Patzwahl R, Meier V, Ramadori G, Mihm S (2001) Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J Virol 75: 1332-1338. doi: 10.1128/JVI.75.3.1332-1338.2001 (Pubitemid 32097955)
7. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, et al. (2004) Interferon type I gene expression in chronic hepatitis C. Lab Invest 84: 1148-1159. doi: 10.1038/labinvest.3700135 (Pubitemid 39128260)
8. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW (2002) Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 160: 641-654. doi: 10.1016/S0002-9440(10)64884-5 (Pubitemid 34160342)
9. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, et al. (2002) Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62: 3939-3944. doi: (Pubitemid 34791056)
10. Heim MH (2009) HCV innate immune responses. Viruses 1: 1073-1088. doi: 10.3390/v1031073
11. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801. doi: 10.1038/nature08463
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401. doi: 10.1038/nature08309
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104. doi: 10.1038/ng.447
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109. doi: 10.1038/ng.449
15. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039. doi: 10.1073/pnas.0707882105 (Pubitemid 351754525)
16. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46: 1548-1563. doi: 10.1002/hep.21853 (Pubitemid 350155537)
17. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509. doi: 10.1053/j.gastro.2010.04.049
18. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896. doi: 10.1002/hep.23912
19. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140: 1021-1031. doi: 10.1053/j.gastro.2010.11.039
20. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, et al. (2012) Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55: 20-29. doi: 10.1002/hep.24623
21. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164-171.doi: 10.1038/ng.2521
22. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, et al. (2013) IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 210: 1109-1116. doi: 10.1084/jem.20130012
23. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, et al. (2013) Association of the IFNL4-DeltaG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis. doi: 10.1093/infdis/jit433
24. Hennig H, Luhm J, Hartwig D, Kluter H, Kirchner H (2001) A novel RT-PCR for reliable and rapid HCV RNA screening of blood donations. Transfusion 41: 1100-1106. doi: (Pubitemid 32848085)
25. Amanzada A, Goralczyk AD, Schneider S, Moriconi F, Lindhorst A, et al. (2012) High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and gamma-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study. Digestion 86: 218-227. doi: 10.1159/000339879
26. Gaunt TR, Rodriguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8: 428. doi: 10.1186/1471-2105-8-428
27. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, et al. (2012) Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28-Bunfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56: 444-454. doi: 10.1002/hep.25647
28. Jouan L, Melancon P, Rodrigue-Gervais IG, Raymond VA, Selliah S, et al. (2010) Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease. J Hepatol 52: 167-175. doi: 10.1016/j.jhep.2009.11.011
29. Bigger CB, Brasky KM, Lanford RE (2001) DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75: 7059-7066. doi: 10.1128/JVI.75.15.7059-7066.2001 (Pubitemid 32641593)
30. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99: 15669-15674. doi: 10.1073/pnas.202608199 (Pubitemid 35403989)